JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).

EP: 1.A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

EP: 2.Molecular Profiling in MPNs: Enhancing Diagnostic Insights

Now Viewing

EP: 3.JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

EP: 4.Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease

EP: 5.Advances in MPN Management: Insights From MANIFEST-2 and Beyond

EP: 6.Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

EP: 7.Academic Perspectives on the Evolving Treatment Landscape in MPNs

Video content above is prompted by the following:

1. Please discuss how advances in JAK V617F monitoring have empowered you to better assess disease status and guide treatment decisions.
2. Please share how risk assessment tools have transformed your ability to optimize treatment selection in patients with MPNs.

Recent Videos